Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis. 2011;15(3):597–609.
Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis. 2011;15(3):627–39.
Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis. 2011;15(3):611–26.
Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011;15(3):515–36.
• Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376(9751):1467–75. This 14 day study showed for the first time that a non-interferon combination of DAAs was capable of profound viral suppression in both naïve and null non-responders HCV patients.
•• Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216–24. This is the first US proof of concept study that demonstrated that a combination of DAAs can achieve a HCV cure without the use of interferon.
Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):742–8.
Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50.PubMedCrossRef
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.
Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2011;55(3):749–58.
Vertex announces 12-week on-treatment data and SVR4 from Phase 2 Study of interferon-free (all-oral) treatment regimen of INCIVEK®, VX-222 and ribavirin in people with genotype 1 hepatitis C.; Available at: http://investors.vrtx.com/releases.cfm?hdr02=press
. Accessed March 2012.
Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141(6):2047–55; quiz e2014.
Zeuzem S, Asselah T, Angus P, et al. High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and PEGIFN/Ribavirin—the Sound-C1 Study. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #249.
Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the Sound-=C2 study. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #LB15.
•• Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/− ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #101. This is the first study to demonstrate that it is possible to achieve a sustained virological response with an interferon-free combination of DAAs in patients with cirrhosis.
Pawlotsky JM, Flisiak R, Rasenack J, et al. Once daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #LB-11.
Pawlotsky JM, Sarin SK, Foster GR, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1405.
Sulkowski MS, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rates in treatment-naïve HCV genotype 1a and 1b patients treated for 12 or 24 weeks with an interferon-free all-oral quad regimen: interim results. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1421.
Lawitz E, Poordad F, Kowdley K, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91 % treatment-naïve HCV IL28B-CC genotype-1-infected subjects. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #13.
Lawitz E, Poordad F, Krowdley K, et al. 12-Week interferon-free regimen of ABT-450/r+ABT-333+Ribavirin achieved SVR12 in up to 95 % of treatment-naive HCV genotype-1-infected subjects with lower response rates in HCV genotype-1-infected previous non-responders. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1399.
•• Sulkowski MS, Lawitz E, Hinestrosa F, et al. Potent viral suppression with all-oral combination therapy with daclatasvir (NS5A Inhibitor) and PSI-7977 (NS5B Inhibitor), +/− ribavirin, in treatment-naive patients with chronic HCV infection. Presented at EASL Conference. Barcelona, Spain. April 18–22, 2012.Poster #1422. This study demonstrated that the combination of a NS5A inhibitor and a NI for 24 weeks represent a potent non-interferon combination that achieved 100 % SVR4 in all patients with HCV genotype 1 even without RBV.
Gane E, Stedman CA, Hyland R, et al. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. The 62nd Annual Meeting of the Association for the Study of Liver Diseases, November 4–8, 2012, San Francisco, CA. Abstract #34.
Gane E, Stedman CA, Hyland R, et al. ELECTRON: once daily GS-7977 plus ribavirin in HCV GT 1/2/3. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1113.
Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment-naïve Hepatitis C patients. Available at:
. Accessed on: April 2012.